Clinical trial
Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for…
NCT00417248 · Nasser Hanna, M.D., Other · Terminated
Key facts
| NCT number | NCT00417248 |
|---|---|
| Title | Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer |
| Official title | A Phase II Trial of Concurrent Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib in Patients With Inoperable Stage III Non-Small Cell Lung Cancer (NSCLC): Hoosier Oncology Group LUN06-107 |
| Lead sponsor | Nasser Hanna, M.D., Other |
| Collaborators | Bayer Industry Amgen Walther Cancer Institute |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Cancer |
| Intervention type | Drug, Procedure |
| Interventions | Cisplatin, Etoposide, Radiotherapy, Sorafenib |
| Enrollment | 8 |
| Start date | Jun 1, 2007 |
| Primary completion | Apr 1, 2008 |
| Completion | Apr 1, 2008 |
| First posted | Dec 29, 2006 |
| Last update posted | Jul 25, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: